October 2026 biotech catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

132 verified catalyst event(s) dated in October 2026, each linked to its official source. Verified as of 2026-09-20.

Date	Event	Company	Drug	Official source & verification
2026-10 (month) in 11d ESTIMATED	READOUT A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Phase 1/2 · Type 1 Diabetes Mellitus	Sernova Biotherapeutics Inc.	Sernova Cell Pouch	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Y Phase 3 · Systemic Juvenile Idiopathic Arthritis	LLY ELI LILLY & Co	Baricitinib, Tocilizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Check Phase 1/2 · Select Advanced Solid Tumors	IMCR Immunocore Holdings plc	Brenetafusp, Brenetafusp and pembrolizum	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients Phase 2 · Melanoma, Head and Neck Squamous Cell Carcinoma	Vyriad, Inc.	VV1, Cemiplimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advan Phase 1/2 · High-grade Glioma, Solid Tumor, Unspecified, Child	Laminar Pharmaceuticals	LAM561	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcuta Phase 3 · Primary Immune Thrombocytopenia	ARGX ARGENX SE	efgartigimod PH20 SC	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus V Phase 3 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Loxo Oncology, Inc.	Pirtobrutinib, Venetoclax, Rituximab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evalua Phase 3 · Coronary Artery Disease	MedTrace Pharma A/S	[O-15]-Water PET Myocardial Perfusion Im	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects Phase 3 · Plaque Psoriasis	Organon and Co	tapinarof cream, 1%	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular De Phase 2 · Age-Related Macular Degeneration	NVS NOVARTIS AG	Iptacopan (LNP023)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Dazucorilant in Patients With Amyotrophic Lateral Sclerosis Phase 2 · Amyotrophic Lateral Sclerosis	CORT CORCEPT THERAPEUTICS INC	Dazucorilant 300 mg, Dazucorilant 150 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Phase 3 · AMD, nAMD	ABBV AbbVie Inc.	ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT SPEARHEAD-3 Pediatric Study Phase 1/2 · Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST)	USWM CT, LLC	Afamitresgene autoleucel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Phase 3 · Focal Onset Seizures	XENE Xenon Pharmaceuticals Inc.	XEN1101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS) Phase 2 · Respiratory Distress Syndrome, Acute	GEn1E Lifesciences	GEn-1124	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Phase 1/2 · Cushing Syndrome, Cushing Disease	Crinetics Pharmaceuticals Inc.	atumelnant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subj Phase 2/3 · Oral Squamous Cell Carcinoma	Privo Technologies	PRV211 (Intraoperative Cisplatin System)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Phase 2 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma	Taiho Oncology, Inc.	Futibatinib, Pembrolizumab, Cisplatin, 5	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study YL201 in Patients With Selected Advanced Solid Tumors Phase 1/2 · Advanced Solid Tumor	MediLink Therapeutics (Suzhou) Co.	YL201 for Injection	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Phase 2/3 · Dementia Moderate, Dementia, Mild	Actinogen Medical	Xanamem	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pe Phase 3 · Central Precocious Puberty	Debiopharm International SA	Debio 4326	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Part Phase 3 · Heart Failure, Systemic Inflammation	NVO NOVO NORDISK A S	Ziltivekimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes Phase 3 · Type 2 Diabetes	LLY ELI LILLY & Co	Retatrutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory F Phase 2/3 · Focal Epilepsy	BHVN Biohaven Ltd.	BHV-7000, BHV-7000	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participant Phase 2 · Alzheimer Disease	ABOS Acumen Pharmaceuticals, Inc.	sabirnetug	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) Phase 2 · Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease	Endeavor Biomedicines, Inc.	ENV-101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urtica Phase 3 · Chronic Spontaneous Urticaria	CLDX Celldex Therapeutics, Inc.	barzolvolimab, Matching placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urtica Phase 3 · Chronic Spontaneous Urticaria	CLDX Celldex Therapeutics, Inc.	barzolvolimab, Matching placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency Phase 2 · Gene Mutations, Pseudoxanthoma Elasticum	Inozyme Pharma	INZ-701	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Phase 3 · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)	MIRM Mirum Pharmaceuticals, Inc.	Maralixibat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration Phase 3 · Wet Age Related Macular Degeneration, wAMD	EYPT EyePoint, Inc.	EYP-1901, Aflibercept (2.0 mg)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Prel Phase 1/2 · Alopecia Areata (AA)	Aldena Therapeutics	ALD-102 Solution	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Phase 2 · Eosinophilic Esophagitis	PHAT Phathom Pharmaceuticals, Inc	Vonoprazan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Partici Phase 2 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus	Immunovant Sciences GmbH	IMVT-1402	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participan Phase 2 · Hypertension, Uncontrolled Hypertension	VNDA Vanda Pharmaceuticals Inc.	iloperidone	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Assess Anktiva in Patients With Long Covid-19. Phase 2 · Long COVID	IBRX ImmunityBio, Inc.	N-803 (IL-15 Superagonist)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Co Phase 3 · Congenital Pseudarthrosis of Tibia	Novadip Biosciences	NVD003, Iliac Crest Bone Graft	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study Evaluating TRIV-509 in Atopic Dermatitis Phase 2 · Atopic Dermatitis	Triveni Bio	TRIV-509	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Phase 2 · Cognitive Impairment Associated With Schizophrenia (CIAS)	Kynexis B.V.	KYN-5356 low dose, KYN-5356 Medium Dose,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Heal Phase 1/2 · Norovirus	COCP Cocrystal Pharma, Inc.	CDI-988, Snow Mountain Virus	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europ Phase 3 · Neuromuscular Agents, Peripheral Nervous System Agents	Merz Aesthetics GmbH	NT 201, NT 201 Placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uvei Phase 2 · Non-infectious Anterior Uveitis	Novaliq GmbH	Tacrolimus ophthalmic solution	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Phase 2 · Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)	Qlaris Bio, Inc.	QLS-111 Ophthalmic Solution (0.015%), QL	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Study of DISC-0974-201 in Participants With IBD and Anemia Phase 2 · Inflammatory Bowel Disease (IBD), Anemia	IRON Disc Medicine, Inc.	DISC-0974	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Di Phase 2 · Type 2 Diabetes	Housey Healthcare ULC	HP-211	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Fu Phase 4 · Dry Eye Disease (DED)	Andover Research Eye Institute	Preservative Free Polyethylene glycol 40	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treat Phase 2 · Forehead Lines	ABBV AbbVie Inc.	AGN-151586	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d CONFIRMED	ADCOM Vaccines and Related Biological Products Advisory Committee Vaccines and Related Biological Products Advisory Committee	Vaccines and Related Biological Pr	AdComm review	Federal Register (FDA notice) ↗ ✓ Source-checked 2026-09-20 Scheduled FDA meeting date
2026-10-02 in 12d ESTIMATED	READOUT Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atro Phase 4 · Spinal Muscular Atrophy	Genentech, Inc.	Risdiplam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-02 in 12d ESTIMATED	READOUT Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Le Phase 1/2 · Leptomeningeal Metastasis	CNSY CERENOME, INC.	186RNL	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-02 in 12d ESTIMATED	READOUT A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy Phase 3 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-861	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-05 in 15d ESTIMATED	READOUT A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polyc Phase 3 · Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis	Swedish Orphan Biovitrum	Pacritinib, Physician's Choice medicatio	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-05 in 15d ESTIMATED	READOUT A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 3 Phase 1/2 · Epstein-Barr Virus Infection	ModernaTX, Inc.	mRNA-1189	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-05 in 15d ESTIMATED	READOUT A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis As Phase 3 · Psychosis Associated With Alzheimer's Disease	Karuna Therapeutics, Inc., a Brist	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-05 in 15d ESTIMATED	READOUT A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Seve Phase 2/3 · Generalized Myasthenia Gravis	UCB Biopharma SRL	rozanolixizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-06 in 16d ESTIMATED	READOUT A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Part Phase 3 · Idiopathic Pulmonary Fibrosis	BMY BRISTOL MYERS SQUIBB CO	BMS-986278, BMS-986278 Placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-07 in 17d ESTIMATED	READOUT Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥ Phase 3 · Atopic Dermatitis	REGN REGENERON PHARMACEUTICALS, I	Dupilumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-07 in 17d ESTIMATED	READOUT A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants Phase 1/2 · RSV Respiratory Syncytial Virus	AZN ASTRAZENECA PLC	AZD6489, Licensed RSV vaccine #1, Licens	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-08 in 18d ESTIMATED	READOUT A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participant Phase 2 · Renal Cell Carcinoma	Hoffmann-La Roche	Tobemstomig, Tiragolumab, Pembrolizumab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-09 in 19d ESTIMATED	READOUT Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W Phase 3 · Hidradenitis Suppurativa	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-09 in 19d ESTIMATED	READOUT Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W Phase 3 · Hidradenitis Suppurativa	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-10 in 20d ESTIMATED	READOUT Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus Phase 3 · Type 2 Diabetes	Hangzhou Zhongmei Huadong Pharmace	HDM1002 200 mg, HDM1002 400 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-12 in 22d ESTIMATED	READOUT A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and H Phase 3 · Paroxysmal Nocturnal Hemoglobinuria	REGN REGENERON PHARMACEUTICALS, I	Ravulizumab, Pozelimab, Cemdisiran, Ecul	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-12 in 22d ESTIMATED	READOUT A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-98634 Phase 1/2 · Multiple Myeloma	BMY BRISTOL MYERS SQUIBB CO	CC-92480, Tazemetostat, BMS-986158, Tram	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-12 in 22d ESTIMATED	READOUT A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Particip Phase 3 · Metastatic Castrate-sensitive Prostate Cancer	Janssen Research & Development, LL	Apalutamide, Androgen-deprivation Therap	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-13 in 23d ESTIMATED	READOUT A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Cli Phase 1/2 · Canavan Disease	Aspa Therapeutics	AAV9 BBP-812	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-13 in 23d ESTIMATED	READOUT Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With Phase 2 · Idiopathic Pulmonary Fibrosis	Daewoong Pharmaceutical Co. LTD.	DWN12088	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-13 in 23d ESTIMATED	READOUT A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants Phase 1/2 · Melanoma, Hodgkin Lymphoma	GlaxoSmithKline	Cobolimab, Dostarlimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-14 in 24d ESTIMATED	READOUT A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab ( Phase 3 · Chronic Rhinosinusitis With Nasal Polyps	SNY Sanofi	Itepekimab (SAR440340), Mometasone furoa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-14 in 24d ESTIMATED	READOUT ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Phase 3 · Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets	Inozyme Pharma	INZ-701	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT Microdystrophin Gene Transfer Study in Adolescents and Children With DMD Phase 1/2 · Duchenne Muscular Dystrophy	SLDB Solid Biosciences Inc.	SGT-001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients Phase 2 · Ovarian Neoplasm Epithelial, Ovarian Cancer	CanariaBio Inc.	Oregovomab, Paclitaxel, Carboplatin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Phase 3 · Ischemic Stroke; Ischemic Attack, Transient	Janssen Research & Development, LL	Milvexian	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema Phase 1/2 · Diabetic Macular Edema	Eclipse Life Sciences, Inc.	EC-104 high dose, EC-104 low dose, Dexam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combin Phase 2 · Metastatic Castration Resistant Prostate Cancer (mCRPC)	NVS NOVARTIS AG	AAA617, ARPI: Abiraterone, ARPI: Enzalut	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial Phase 2 · Adult Obesity, Weight Management	Eccogene	ECC4703, Semaglutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-16 in 26d ESTIMATED	READOUT An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Ve Phase 1/2 · Non-Hodgkins Lymphoma	Hoffmann-La Roche	Glofitamab, Atezolizumab, Obinutuzumab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-18 in 28d ESTIMATED	READOUT Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients Wit Phase 2/3 · Type 2 Diabetes	Han Xu, M.D., Ph.D., FAPCR, Medica	Farxiga® (dapagliflozin) + Onglyza® (sax	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Phase 4 · Asthma	AZN ASTRAZENECA PLC	Benralizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Plac Phase 3 · Systemic Lupus Erythematosus	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Com Phase 3 · Systemic Lupus Erythematosus	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclit Phase 2 · Breast Cancer	Hoffmann-La Roche	Tobemstomig, Pembrolizumab, Nab-Paclitax	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop Phase 2 · Atopic Dermatitis	PFE PFIZER INC	PF-07275315, PF-07264660	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 3 · Prurigo Nodularis	INCY INCYTE CORP	Povorcitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 3 · Prurigo Nodularis	INCY INCYTE CORP	Povorcitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-20 in 30d ESTIMATED	READOUT A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Sym Phase 2/3 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus	BIIB BIOGEN INC.	Litifilimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-20 in 30d ESTIMATED	READOUT First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors Phase 1/2 · Advanced Solid Tumor, Metastatic Solid Tumor	Daiichi Sankyo	DS-3939a	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-20 in 30d ESTIMATED	READOUT A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Phase 3 · Atopic Dermatitis	LEO Pharma	Tralokinumab + TCS	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-20 in 30d ESTIMATED	READOUT A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Partic Phase 4 · Neovascular Age-related Macular Degeneration (nAMD)	Hoffmann-La Roche	Faricimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-20 in 30d ESTIMATED	READOUT A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participan Phase 3 · Schizophrenia	Otsuka Pharmaceutical Development	SEP-363856	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-22 in 1mo ESTIMATED	READOUT A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multi Phase 3 · Progressive Multiple Sclerosis (PMS)	Hoffmann-La Roche	Ocrelizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-22 in 1mo ESTIMATED	READOUT A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifa Phase 1/2 · Renal Cell Carcinoma	Merck Sharp & Dohme LLC	Belzutifan, Palbociclib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-22 in 1mo ESTIMATED	READOUT A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndro Phase 3 · Sjögren's Syndrome (SS)	AMGN AMGEN INC	Dazodalibep	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-23 in 1mo ESTIMATED	READOUT A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combinati Phase 2 · Carcinoma, Non-Small-Cell Lung	AZN ASTRAZENECA PLC	Durvalumab, Tremelimumab, Pemetrexed, Pe	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-26 in 1mo ESTIMATED	READOUT A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodulari Phase 3 · Prurigo Nodularis	Galderma R&D	Nemolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-26 in 1mo ESTIMATED	READOUT Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Additio Phase 3 · Coronary Artery Disease	NVS NOVARTIS AG	Inclisiran sodium 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-27 in 1mo ESTIMATED	READOUT Study of Novel Immunomodulators as Monotherapy and in Combination With Anticance Phase 2 · Hepatocellular Carcinoma, Biliary Tract Cancer	AZN ASTRAZENECA PLC	Volrustomig, Bevacizumab, Lenvatinib, Ri	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-28 in 1mo ESTIMATED	READOUT A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Phase 2/3 · Spinal Muscular Atrophy (SMA)	Hoffmann-La Roche	RO7204239, Risdiplam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-28 in 1mo ESTIMATED	READOUT A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Phase 3 · Carcinoma, Renal Cell	Merck Sharp & Dohme LLC	Belzutifan, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-28 in 1mo ESTIMATED	READOUT An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevi Phase 3 · Biliary Atresia	Albireo, an Ipsen Company	Odevixibat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-28 in 1mo ESTIMATED	READOUT A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-rela Phase 2 · Macular Degeneration, Age-related, Geographic Atrophy	Boehringer Ingelheim	BI 771716, Pegcetacoplan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-29 in 1mo ESTIMATED	READOUT Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in P Phase 3 · Primary Immune Thrombocytopenia (ITP)	NVS NOVARTIS AG	Ianalumab, Corticosteroids	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-29 in 1mo ESTIMATED	READOUT Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia Phase 2 · Post-Bariatric Hypoglycemia	RECORDATI GROUP	Pasireotide Diaspartate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease T Phase 2 · Gaucher Disease Type 1, Gaucher Disease Type 3	Genzyme, a Sanofi Company	venglustat (GZ402671), imiglucerase	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumo Phase 1/2 · Solid Tumor, Adult	Nouscom SRL	GAd-209-FSP low dose, MVA-209-FSP low do	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrol Phase 3 · Melanoma	PFE PFIZER INC	Encorafenib, Binimetinib, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients Phase 3 · Breast Cancer	Laekna Limited	Afuresertib, Afuresertib/placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Thera Phase 3 · Cystic Fibrosis	Vertex Pharmaceuticals Incorporate	VX-121/TEZ/D-IVA	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL Phase 2 · Advanced Cancer, Metastatic Cancer	Mirati Therapeutics Inc.	Adagrasib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G Phase 1/2 · Malignant Neoplasm	Tyligand Pharmaceuticals (Suzhou)	TSN1611, TSN1611, TSN1611, TSN1611	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS Phase 1/2 · Prostate Cancer, Prostate Cancer (Adenocarcinoma)	Antelope Surgical Solutions, Inc	AS1986NS	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT 18F-mFBG Imaging for Myocardial Sympathetic Innervation Phase 2 · Heart Failure, Ischemic Cardiomyopathy	Innervate Radiopharmaceuticals LLC	18F-metaFluorobenzylguanidine, Rubidium-	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT 18F-mFBG Cardiac Uptake With Lewy Body Dementia Phase 2 · Parkinson Disease (PD), Lewy Body Dementia (LBD)	Innervate Radiopharmaceuticals LLC	18F-MFBG	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer Phase 1/2 · Carcinoma, Non-Small-Cell Lung	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-788	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-re Phase 1/2 · Prostate Cancer Metastatic	ORN Orion Group Holdings Inc	ODM-208, Midazolam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participan Phase 3 · Muscular Dystrophy, Duchenne	SRPT Sarepta Therapeutics, Inc.	Eteplirsen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-788, Pemetrexed, Cisplatin, Carbopla	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic So Phase 1/2 · Advanced/Metastatic Solid Tumors	ADAG Adagene Inc.	ADG126, Pembrolizumab (KEYTRUDA®)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischem Phase 2 · Congestive Heart Failure	AskBio Inc	AB-1002	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advan Phase 3 · Breast Cancer, Advanced Breast Cancer	OLMA Olema Pharmaceuticals, Inc.	Palazestrant, Fulvestrant, Anastrozole,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Phase 3 · Asthma	Teva Branded Pharmaceutical Produc	TEV-56248, Albuterol sulfate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT Study of JK07 in Patients With Chronic Heart Failure Phase 2 · Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction	Salubris Biotherapeutics Inc	JK07	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections o Phase 3 · Geographic Atrophy	ANNX Annexon, Inc.	Vonaprument	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalen Phase 2 · Chronic Lymphocytic Leukemia	Genentech, Inc.	Venetoclax, cBTKi Monotherapy	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC Phase 2 · MTAP-deleted NSCLC	AMGN AMGEN INC	anvumetostat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study to Investigate LP352 in Children and Adults With Developmental and Epile Phase 3 · Developmental and Epileptic Encephalopathy	Longboard Pharmaceuticals	LP352	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study of Setmelanotide in Patients With Prader-Willi Syndrome Phase 2 · Prader-Willi Syndrome, Obesity	RYTM RHYTHM PHARMACEUTICALS, INC.	Setmelanotide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study of SPY072 in Rheumatic Disease Phase 2 · Rheumatoid Arthritis, Psoriatic Arthritis	SYRE Spyre Therapeutics, Inc.	SPY002-072	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients Phase 1/2 · Glioblastoma (GBM)	Myosin Therapeutics Inc.	MT-125	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological Phase 3 · Relapsing Multiple Sclerosis	TG Therapeutics, Inc.	Ublituximab, Ublituximab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory La Phase 2 · Premature Ejaculation	Kadence Bio	KH-001 ODT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Phase 2 · Vaginal Dysbiosis	Freya Biosciences ApS	FB-301, Chlorhexidine (0.5%) Vaginal Cle	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change